Member Info for appletree1

The insider ownership referred to in the X post by Looking Hot is stated as being very high at 56%. Like the spurious stock analyst targets, that info is massively inaccurate and out of date. That high insider ownership dates from autumn 2024 when the stock started its massive 1100% spike (coincidentally at the exact same time the owner/majority shareholder company MD Nelson Law chose to retire). According to the November 2025 published prospectus it appears he now has no visible holding left (other than perhaps 5% through a nominee) though not a single TR1 was ever filed.

T

Warrants were reduced 10 to 1 by the consolidation too, so none are massively in profit at this low share price level.

Oscar52, your 20k allowance is deployable across both cash and shares ISA's. The budget re-introducing a cap on the cash ISA side of the allowance for under 65's ( there always used to be a cash ISA cap in the past prior to 2017) may well lead to some people allocating the 8k balance of their allowance into a shares ISA to make full use of their 20k allowance. This is clearly a positive move for the market, though what we investors and the industry are really hoping for is the government to take action at some point to steer institutional investors back into investing more in the UK markets and at least partially reverse the massive collapse in investment in the UK that has occurred over the last 25 years. [ The proportion of UK-listed shares held by pension funds has dropped from over 50% in the 1990s to around 4% or less currently and is far lower than seen in practically any other country ].

Yes, Google Finance only lists share prices for the London Stock Exchange in the UK and not (yet) for Aquis Exchange. Live prices are available free of charge on both the AQSE website and ADVFN.

This is just the unaudited interims to 30 June 2024 and says nothing about future plans after the Mode wind-up. They have already said that the stock will be restored to trading/un-suspended when the audited accounts to 31 December 2024 are finalized and published. Hopefully by the time that occurs there will have been some positive developments to report.

Is there any reason why this platform doesn't display RNS info here, unlike for other AQSE stocks like VLRM etc? Surely that is a factor in the lack of volume/ new investors here. How do we get this platform to correct that and add all of the missing announcements?

Trades are not listed as buy or sell by the London Stock Exchange. Trading platforms like this and ADVFN that list trades take the raw Stock Exchange data and reformat it with an algorithm that guesses whether a trade is a buy or sell. If the MMs are taking a live trade that is a buy for a low price eg .61p that is below the mid-point of the advertised book spread (eg the 0.626p mid-point of the 0.60p bid to 0.65p offer spread that applies to this stock currently) off course the algorithm is going to assume it was a sell not a buy. Sometimes the algorithm (? AI driven) gets wise to the MM tricks and spots that the low trade is actually more likely to be a buy, but that takes time/ multiple trades for it to notice patterns in the trades.

What analysts? Nice write-up from Guardian Globe but who are they and who is this Guardian Globe analyst? Why does Guardian Globe have no web footprint when Google-searched and only a Regus virtual office address and no email or working contact form or phone contacts on their contact page and no meaningful info on their About Us page?

How/where does one buy shares in this stock? It isn't accessible to buy on Hargreaves Lansdown (only hold or sell) they say due to MIFID ii regs.

As supplemental to the points made thusfar, whereas our BIT agreement is silent on the seat of arbitration, for guidance on UNCITRAL arbitration legal practice on selecting a seat of arbitration where the parties don't first agree on the issue, the Clifford Chance legal briefing entitled 'SILENT SEATS IN INVESTMENT TREATIES' clearly references the principle of neutrality in selection of the seat of arbitration (and as affirmed in the case-law such as Philip Morris Asia Ltd v Australia). The briefing makes it clear that to respect Article 16 (2) of the UNCITRAL rules the seat selected will not be on the territory of the respondent State or any State whose nationality is asserted by a claimant investor. In my opinion it most likely it will be either Singapore, Hong Kong or Washington.

Almost certainly all buys at the moment. My 1k top-up was at 7.99p just now. It seems likely that the offer price is being held at this level to consolidate before any move higher to the 8.5p.

The MCap is approx £1.26M not £500k. As is often the case, the LSE front page is out of date and doesn't show the correct shares in issue (approx 900M shares).

The paper was published in Indian Heart Journal only four days ago on 14 July 2024.

The second page of the pdf states that the OWAIS winning bid was 65.3%.

Is that the royalty rate that they will pay to GOI ?

Now nearly just three weeks to go for the 6 month cooling-off period to expire. Once that point is reached the BIT arbitration protocol for unilateral referral to tribunal takes effect. Though PAT can presumably submit the referral application ahead of that date the process cannot formally start until then and I would have thought it is usually best practice to wait until just before that point and to then file the application promptly.

Roger65, Peel Hunt would have received a large payment for the placings. It accounts for the approx 0.5Million pound gap between the 6 million raised and the 5.5 million received as per previous RNS. The payment they received was in shares hence why the hold the shares referred to in today's RNS. It is very likely to be only them that are selling in any volume at these low levels . When their holding is sold the SP should rise.

Top-line data is expected to be available in Q2 2024 was the wording on the Half-year report of 28 March 2024. We are already a month into Q2 2024, so it is due soon.

Apparently Astra Zeneca's most profitable drug at the moment is Farxiga. https://www.biospace.com/article/astrazeneca-sees-6-percent-revenue-growth-in-2023-despite-plummeting-covid-19-sales/. They made nearly 6 Billion US Dollars last year from Farxiga, as used to treat Chronic Kidney Disease (CKD) and Diabetes. They are thus VERY keen to see screening for CKD increased. https://www.fiercepharma.com/marketing/astrazeneca-decries-low-kidney-disease-diagnosis-rates-finds-urgent-need-better-screening

Not perfect but the current corporate strategy seems to be a half-way house to a fully cash-conservative model. Spend seems to be around 2 Million annually, with a relatively gradual progression of the African projects in concert with JV partners while waiting on the outcome of the case.